Navigation Links
Van Andel Institute and Children's Memorial Research Center of Chicago Form a Partnership to Facilitate Pediatric Research
Date:2/26/2008

., Medical Research Institute Council Endowed Chair for the President and Scientific Director of CMRC.

XenoBase is the result of five years of research and development in the lab of Craig P. Webb, Ph.D., Director of VARI's Program of Translational Medicine. The system can collect and analyze a wide range of molecular and conventional clinical data to aid researchers in identifying associations between diseases, biomarkers and treatment outcomes. "We are delighted to license this technology to CMRC and demonstrate its effectiveness in supporting different areas of pediatric translational research," said Webb. "We look forward to collaborative efforts through which improved diagnostic and therapeutic strategies can ultimately be introduced to the pediatric population."

The mission of Children's Memorial Research Center is to generate new knowledge leading to advancements in the prevention, diagnosis, and treatment of diseases that affect the development of children through adolescence as well as adult disorders that derive from them. Our multidisciplinary teams of physicians, scientists, technicians, nurses and trainees are committed to making discoveries that will improve the lives of children and their families.

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process.


'/>"/>
SOURCE Children's Memorial Hospital
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer
2. Otho S.A. Sprague Memorial Institute awards Rush nearly $125,000 for new patient-safety project
3. Otho S.A. Sprague Memorial Institute awards Rush $230,000 for childhood obesity prevention
4. Bishop T. D. Jakes Receives The Black Aids Institute 2008 Heroes in the Struggle Award
5. UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders
6. China Holdings Announces Starwood Research Institute Initiates Research Coverage
7. OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence
8. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
9. VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists
10. VEGF neutralization can damage brain vessels, say Schepens Eye Research Institute scientists
11. Dana-Farber Cancer Institute Completes Deployment of MedAptus Infusion Services Module
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 4Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 5TOPAZ Technologies Introduces Biosafety Software Solution 48428 1TOPAZ Technologies Introduces Biosafety Software Solution 48428 2TOPAZ Technologies Introduces Biosafety Software Solution 48428 3As Sleep Improves Grades Seem to Go Up 48427 1As Sleep Improves Grades Seem to Go Up 48427 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 1MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 3